IMGT engineered variant nomenclature: IGHG variants

Citing this table: Lefranc, M.-P. and Lefranc, G., The Immunoglobulin FactsBook, Academic Press, London, UK (458 pages), 2001, ISBN:012441351X

1. Structural and biological properties of human immunoglobulins

2. Human immunoglobulin (IG) chain characteristics

3. IG interchain disulfide bridges per monomer

4. Lysines and cysteines of the Homo sapiens IGHG1, IGKC and IGLC1 and positions in the C-DOMAIN

5. Amino acid positions involved in ADCC, CDC, half life and half-IG exchange

7. Homo sapiens IGHG1 amino acids involved in the interactions with the C1q, FcγR and FCGRT

Species IMGT gene name IMGT engineered variant nomenclature IGHG gene variant description Property modifications
IMGT IGHG gene variant number hinge (h) or CH2 AA and IMGT position in h or CH2 of IGHG gene variant CH3 AA and IMGT position in CH3 of IGHG gene variant ADCC enhancement or reduction, ADCP enhancement, B cell inhibition CDC enhancement or reduction Half-IG exchange reduction, Half-life increase, Knobs-into-holes
Homo sapiens IGHG1 Homsap IGHG1v1 CH2 P1.4 v1 CH2 P1.4 ADCC reduction
Homsap IGHG1v2 CH2 V1.3 v2 CH2 V1.3 ADCC reduction
Homsap IGHG1v3 CH2 A1.2 v3 CH2 A1.2 ADCC reduction
Homsap IGHG1v4 CH2 A114 v4 CH2 A114 ADCC reduction CDC reduction
Homsap IGHG1v5 CH2 W109 v5 CH2 W109 ADCC reduction CDC enhancement
Homsap IGHG1v6 CH2 A85.4, A118, A119 v6 CH2 A85.4, A118, A119 ADCC enhancement
Homsap IGHG1v7 CH2 D3, E117 v7 CH2 D3, E117 ADCC enhancement
Homsap IGHG1v8 CH2 D3, L115, E117 v8 CH2 D3, L115, E117 ADCC enhancement CDC reduction
Homsap IGHG1v9 CH2 L7, P83, L85.2, I88; CH3 L83 v9 CH2 L7, P83, L85.2, I88 CH3 L83 ADCC enhancement
Homsap IGHG1v10 CH2 Y1.3, Q1.2, W1.1, M3, D30, E34, A85.4 v10 CH2 Y1.3, Q1.2, W1.1, M3, D30, E34, A85.4 ADCC enhancement
Homsap IGHG1v11 CH2 E34, D109, M115, E119 v11 CH2 E34, D109, M115, E119 ADCC enhancement
Homsap IGHG1v12 CH2 A1.1, D3, L115, E117 v12 CH2 A1.1, D3, L115, E117 ADCC enhancement
Homsap IGHG1v13 CH2 A1.1, D3, E117 v13 CH2 A1.1, D3, E117 ADCP enhancement
Homsap IGHG1v14 CH2 A1.3, A1.2 v14 CH2 A1.3, A1.2 ADCC reduction CDC reduction
Homsap IGHG1v15 CH2 S118 v15 CH2 S118 CDC enhancement
Homsap IGHG1v16 CH2 W109, S118 v16 CH2 W109, S118 CDC enhancement
Homsap IGHG1v17 CH2 E29, F30, T107 v17 CH2 E29, F30, T107 CDC enhancement
Homsap IGHG1v18 CH3 R1, G109, Y120 v18 CH3 R1, G109, Y120 CDC enhancement
Homsap IGHG1v19 CH2 A34 v19 CH2 A34 CDC reduction
Homsap IGHG1v20 CH2 A105 v20 CH2 A105 CDC reduction
Homsap IGHG1v21 CH2 Y15.1, T16, E18 v21 CH2 Y15.1, T16, E18 Half-life increase
Homsap IGHG1v22 CH2 Y15.1, T16, E18; CH3 K113, F114, H116 v22 CH2 Y15.1, T16, E18 CH3 K113, F114, H116 Half-life increase
Homsap IGHG1v23 CH2 E1.2 v23 CH2 E1.2 ADCC reduction CDC reduction
Homsap IGHG1v24 CH3 L107, S114 v24 CH3 L107, S114 Half-life increase
Homsap IGHG1v25 CH2 E29, F113 v25 CH2 E29, F113 B cell inhibition
Homsap IGHG1v26 CH3 Y22 v26 CH3 Y22 Knob in knobs-into-holes interaction
Homsap IGHG1v27 CH2 C3 v27 CH2 C3 Site-specific drug attachment engineered cysteine
Homsap IGHG1v28 CH2 insC3A v28 CH2 insC3A Site-specific drug attachment engineered cysteine
Homsap IGHG1v29 CH2 A84.4 v29 CH2 A84.4 No N-glycosylation site
Homsap IGHG1v30 CH2 G84.4 v30 CH2 G84.4 No N-glycosylation site
Homsap IGHG1v31 CH3 T86 v31 CH3 T86 Hole in knobs-into-holes interaction
Homsap IGHG1v32 CH3 W22 v32 CH3 W22 Knob in knobs-into-holes interaction
Homsap IGHG1v33 CH3 S22, A24, V86 v33 CH3 S22, A24, V86 Hole in knobs-into-holes interaction
Homsap IGHG1v34 CH3 v34 CH3 G109 Favors hexamerisation
Homsap IGHG1v35 CH2 E29 v35 CH2 E29 CDC enhancement
Homsap IGHG1v36 CH2 Q84.4 v36 CH2 Q84.4 No N-glycosylation site
Homsap IGHG1v37 h S5 v37 h S5 No disulfide bridge inter H-L
Homsap IGHG1v38 CH2 S108, F113 v38 CH2 S108, F113 Abrogation of FcyRIII binding Abrogation of C1q bnding
Homsap IGHG1v39 CH2 F1.3, E1.2, S116 v39 CH2 F1.3, E1.2, S116 ADCC reduction CDC reduction
Homsap IGHG1v40 CH2 A1.3, A1.2, S116 v40 CH2 A1.3, A1.2, S116 ADCC reduction CDC reduction
Homsap IGHG1v41 CH2 F1.3, E1.2 v41 CH2 F1.3, E1.2 ADCC reduction CDC reduction
IGHG2
Homsap IGHG2v1 CH2 L1.3, L1.2, G1.1, G1 v1 CH2 L1.3, L1.2, G1.1, G1 ADCC enhancement
Homsap IGHG2v2 CH2 Q30, L92, S115, S116 v2 CH2 Q30, L92, S115, S116 ADCC reduction CDC reduction
Homsap IGHG2v3 CH2 A1.2, A1, S2, A30, L92, S115, S116 v3 CH2 A1.2, A1, S2, A30, L92, S115, S116 ADCC reduction CDC reduction
Homsap IGHG2v4 CH2 Q14 v4 CH2 Q14 Half-life increase
Homsap IGHG2v5 CH3 L107 v5 CH3 L107 Half-life increase
Homsap IGHG2v6 CH2 Q14, CH3 L107 v6 CH2 Q14 CH3 L107 Half-life increase
IGHG3 Homsap IGHG3v1 CH3 H115 v1 CH3 H115 Half-life increase
IGHG4
Homsap IGHG4v1 CH2 L1.3 v1 CH2 L1.3 ADCC enhancement
Homsap IGHG4v2 CH2 P116 v2 CH2 P116 CDC enhancement
Homsap IGHG4v3 CH2 E1.2 v3 CH2 E1.2 ADCC reduction CDC reduction
Homsap IGHG4v4 CH2 A1.3, A1.2 v4 CH2 A1.3, A1.2 ADCC reduction CDC reduction
Homsap IGHG4v5 h P10 v5 h P10 Half-IG exchange reduction
Homsap IGHG4v6 CH3 K88 v6 CH3 K88 Half-IG exchange reduction
Homsap IGHG4v21 CH2 Y15.1, T16, E18 v21 CH2 Y15.1, T16, E18 Half-life increase
Homsap IGHG4v22 CH2 T16, P91, CH3 A114 v22 CH2 T16, P91 CH3 A114 Half-life increase
Homsap IGHG4v36 CH2 Q84.4 v36 CH2 Q84.4 No N-glycosylation site
Mus musculus IGHG2B
Musmus IGHG2Bv1 CH2 L1.2 v1 CH2 L1.2 ADCC enhancement
Musmus IGHG2Bv2 CH2 A101 v2 CH2 A101 CDC reduction
Musmus IGHG2Bv3 CH2 A103 v3 CH2 A103 CDC reduction
Musmus IGHG2Bv4 CH2 A105 v4 CH2 A105 CDC reduction
CNRS Université de Montpellier European Commission

© Copyright 1995-2021 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT